Alnylam Pharmaceuticals, Inc. Earnings

Alnylam Pharmaceuticals, Inc.’s revenue jumped 34.9% since last year same period to $593.17Mn in the Q4 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 18.42% jump in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit jumped 39.24% since last year same period to $-83.76Mn in the Q4 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 24.92% jump in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin jumped 54.96% since last year same period to -14.12% in the Q4 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 36.6% jump in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a 84.83% jump from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.14.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) jumped 105.45% since last year same period to 0.06 in the Q4 2024. This indicates that the Alnylam Pharmaceuticals, Inc. has generated 105.45% annual rate of jump in its earning per share (EPS) in the last 4 quarters.